Streetbeat News

Products Services

TCBP

TC BioPharm (TCBP) has dosed the sixth patient in its ACHIEVE study, which focuses on treating patients with Acute Myeloid Leukemia (AML).

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:03 pm

ALLR

Allarity Therapeutics received a Wells Notice from the SEC regarding its disclosures about meetings with the FDA concerning its NDA for Dovitinib or Dovitinib-DRP. The company has a cash balance of $20 million, expected to last until 2026, and has paused its ATM usage. Additionally, Allarity's Stenoparib shows extended Phase 2 clinical benefits.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:02 pm

JNJ

Johnson & Johnson has submitted a supplemental new drug application to the FDA for the approval of SPRAVATO CIII nasal spray, aimed at treating treatment-resistant depression.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:01 pm

TACT

TransAct Technologies has started the rollout of its BOHA! Terminal 2 to all 42 Jet Food Stores for fresh food labeling, with full deployment expected by September.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:01 pm

SSKN

STRATA Skin Sciences has received approval for its XTRAC Momentum 1.0 device in Japan, potentially expanding its market reach and revenue opportunities.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:00 pm

RTX

Raytheon UK, a subsidiary of RTX Corp, successfully tested its High-Energy Laser Weapon System (HELWS) integrated onto a British Army combat vehicle. This marks the first test of its kind in the UK and a significant advancement in the UK's Land Laser Directed Energy Weapon (LDEW) Demonstrator programme.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 11:56 am

VVX

V2X, Inc. (NYSE:VVX) has secured a $48.5 million contract with the U.S. Army for the Gateway Mission Router (GMR), enhancing battlefield communications. The four-year IDIQ contract highlights V2X's role in national defense.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 11:47 am

ITRM

Iterum Therapeutics (NASDAQ: ITRM) has commenced a rights offering, distributing subscription rights to shareholders and eligible warrant holders to purchase 8,503,800 units at $1.21 per unit. This move aims to support the development of next-generation antibiotics.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 11:43 am

TSLA

Elon Musk announced a delay in the production and sales timeline for Tesla's humanoid robot, Optimus. Initially expected to be available for external customers by the end of 2025, the new timeline suggests high production for other companies by 2026. Tesla plans to have low production for internal use next year.

Portfolio Pulse from Anan Ashraf

July 22, 2024 | 11:41 am

RTX

RTX (NYSE:RTX) has completed the preliminary design review for its hybrid-electric propulsion demonstrator engine under the SWITCH project, supported by the EU's Clean Aviation Joint Undertaking. The system aims to improve engine efficiency and reduce fuel burn and emissions for future short- and medium-range aircraft.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 11:41 am